Hematological Malignancies
Conditions
Brief summary
This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels. Indication: Hematological malignancies (multiple myeloma \[MM\], mantle cell lymphoma \[MCL\], diffuse large B-cell lymphoma \[DLBCL\], adult T-cell leukemia-lymphoma \[ATL\], and indolent non Hodgkin lymphomas such as follicular lymphoma \[FL\] and chronic lymphocytic leukemia \[CLL\]/small lymphocytic lymphoma \[SLL\]).
Detailed description
This will be a dose escalation study in subjects with selected hematological malignancies. KPG-818 will be used in combination with dexamethasone in subjects with MM, and as monotherapy for other selected hematological malignancies. Each dose of KPG-818 will be administered orally until the completion of treatment cycles, or progressive disease (PD), unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The highest dose level which may be tested is 5 mg KPG-818 and dose levels 2, 3, 4, and 5 mg and/or intermediate dosing or alternative dosing schedule may be explored. Each dose level (1-4) will be tested using the standard 3+3 design. DLT will be assessed during the DLT evaluation period (Cycle 1) and the treatment of study is divided into 6 cycles.
Interventions
DRUGKPG-818
The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg. Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The treatment of study is divided into 6 cycles.
Sponsors
Kangpu Biopharmaceuticals, Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
This is a open label Phase I study
Intervention model description
Dose escalation will use a standard 3+3 approach to establish a maximum tolerated dose (MTD), and the initial escalation dose level will be 2mg/day. Subjects may be enrolled at dose levels 2, 3, 4, and 5 mg and/or intermediate dosing or alternative dosing schedule
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥ 18 years of age 2. Willing and able to provide written consent. 3. Willing and able to adhere to the study visit schedule and other protocol requirements. 4. Hematocytological or pathological diagnosis of MM, MCL, DLBCL, ATL, indolent lymphoma, such as FL and CLL/SLL, etc. 5. Subjects who have relapsed from or are refractory to MM, MCL, DLBCL, ATL, indolent lymphoma, such as FL and CLL/SLL. 6. Have measurable or assessable disease. 7. Meet the laboratory requirements: 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 9. Males and females of childbearing potential must agree to use at least two methods of contraception and continue until 3 months after the completion of study treatment.
Exclusion criteria
1. Has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. Currently enrolled in another clinical study, except observational studies. 3. Has known active central nervous system metastases and/or lymphomatous meningitis. 4. Persisting toxicities related to prior anticancer treatment \> Grade 1. 5. Major surgery or significant traumatic injury within 6 weeks prior to Screening or planned major surgery during the study period. 6. Received live attenuated vaccine within 4 weeks of first dose. 7. Subjects with gastrointestinal disease that may significantly alter the absorption of the study drug. 8. Subjects with a plasma cell leukemia. 9. Subjects with prior history of malignancies, other than MM, lymphoma, or CLL/SLL, unless the subject has been free of the disease for ≥ 5 years. 10. Has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, or pomalidomide. 11. Has known or suspected hypersensitivity to the excipients contained in the formulation of investigational product (IP). 12. Has been treated with an investigational agent (i.e., an agent not commercially available) within 28 days of initiating IP. 13. Prior treatment of any inhibitors of PD-1 or PD-L1 within 3 months prior to initiating IP. 14. Has any one of the following: * Clinically significant abnormal ECG finding at Screening. * Congestive heart failure. * Myocardial infarction within 12 months prior to initiating IP. * Unstable or poorly controlled angina pectoris, including the Prinzmetal variant of angina pectoris. * Peripheral neuropathy ≥ Grade 2. * Subject has taken a strong inhibitor or inducer of CYP3A4/5 including grapefruit, St. John's Wort or related products within 2 weeks prior to dosing and during the course of study. 15. Has current or prior use of immunosuppressive medication within 14 days prior initiating IP. 16. Subject known to test positive for human immunodeficiency virus, active hepatitis B, or active hepatitis C. 17. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis. 18. Subject is a female who is pregnant, nursing, or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Phase 2 Dose (RP2D) | Up to 4 weeks of treatment | Maximum tolerated dose defined as the highest dose level at which 33% or less subjects experience DLT as defined by the protocol. |
| Treatment-Emergent Adverse Events [Safety and Tolerability] | Up to 6 months of treatment | Number of Treatment-Emergent Adverse Events(TEAE), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and changes from baseline in laboratory parameters, vital signs, and ECG. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK profile of KPG-818: area under the plasma concentration-time profile (AUC) from time zero to the last quantifiable concentration (AUC0-t). | Up to 4 weeks of treatment | — |
| PK profile of KPG-818: AUC from time zero extrapolated to infinity (AUC0-∞). | Up to 4 weeks of treatment | — |
| PK profile of KPG-818: AUC within a dosing interval (AUC0-τ). | Up to 4 weeks of treatment | — |
| PK profile of KPG-818: apparent total plasma clearance (CL/F). | Up to 4 weeks of treatment | — |
| PK profile of KPG-818: apparent total plasma clearance at steady-state (CLss/F). | Up to 4 weeks of treatment | — |
| PK profile of KPG-818: apparent volume of distribution (Vz/F) | Up to 4 weeks of treatment | — |
| PK profile of KPG-818: apparent volume of distribution at steady-state (Vss). | Up to 4 weeks of treatment | — |
| PK profile of KPG-818: maximum observed plasma concentration (Cmax). | Up to 4 weeks of treatment | — |
| Assessment of clinical activity: objective response rate (ORR). | Up to 6 months of treatment | Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL). |
| Assessment of clinical activity: disease control rate (DCR). | Up to 6 months of treatment | Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL). |
| Assessment of clinical activity: time to response, duration of response. | Up to 6 months of treatment | Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL). |
| Assessment of clinical activity: progression-free survival. | Up to 6 months of treatment | Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL). |
| Assessment of clinical activity: event-free survival (EFS), and transplantation rate (TR). | Up to 6 months of treatment | Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL). |
| PK profile of KPG-818: apparent plasma terminal elimination. half-life (t1/2) | Up to 4 weeks of treatment | — |
| PK profile of KPG-818: time of the maximum observed plasma concentration (Tmax) | Up to 4 weeks of treatment | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Biomarkers of KPG-818 | Up to 6 months of treatment | Aiolos and Ikaros in peripheral blood mononuclear cell (PBMC) |
Countries
United States
Outcome results
None listed